Conversely, paclitaxel does not interfere with IAP-2 expression, and thus contributes efficiently to limit cell migration and subsequent metastatic potential, which accounts for the survival effect of RASSF1A promoter gene methylation in paclitaxel-treated NSCLC patients (Graphical abstract). The gene discussed is RASSF1; the disease is non-small cell lung carcinoma.